Summary of Significant Accounting Policies - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Segment Revenue
Total Revenue	$ 56,891			$ 55,477			$ 171,334	$ 155,338
Segment Adjusted EBITDA
Total Adjusted EBITDA	(64,012)			(25,315)			(120,970)	(65,365)
Net income (loss)	(89,396)	$ (16,524)	$ (42,026)	(44,645)	$ (36,191)	$ (35,770)	(147,946)	(116,606)
Adjustments
Interest (income) / net	(76)			(53)			(213)	(195)
Other (income) / expense, net	(22)			(445)			(39)	(1,318)
Change in fair value of warrant liabilities	(3,695)			0			(32,989)	0
Income tax benefit	(3,512)			0			(3,512)	0
Depreciation and Amortization	4,681			4,833			14,188	15,532
Amortization Of Acquired Intangible Assets	2,898			0			2,898	0
Stock-based compensation expense	17,409			14,995			37,473	37,222
Total Adjusted EBITDA	(64,012)			(25,315)			(120,970)	(65,365)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue	56,891			55,477			171,334	155,290
Segment Adjusted EBITDA
Total Adjusted EBITDA	(31,967)			(2,468)			(33,232)	(4,925)
Therapeutics
Segment Revenue
Total Revenue	0			0			0	48
Segment Adjusted EBITDA
Total Adjusted EBITDA	(19,916)			(15,051)			(57,046)	(38,886)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	(12,129)			(7,796)			(30,692)	(21,554)
Acquisition related costs
Adjustments
Total Adjusted EBITDA	$ 7,701			$ 0			$ 9,170	$ 0